Skip to main content

Table 4 Logistic regression of possible risk factors and skin rashes.

From: Safety and tolerability of nevirapine-based antiretroviral therapy in HIV-infected patients receiving fluconazole for cryptococcal prophylaxis: a retrospective cohort study

Factors

Odd Ratios

95% confidence interval

Pvalue

Female gender

1.26

0.67–2.39

0.470

Body weight

1.02

0.98–1.05

0.347

Baseline CD4 cell count

1.00

0.99–1.01

0.873

Receiving anti-tuberculous drugs

2.96

1.04–8.47

0.043

Receiving fluconazole

1.56

0.79–3.08

0.201

Receiving Cotrimoxazole

1.21

0.68–2.91

0.594